cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.

@article{Vandeput2009cGMPhydrolyticAA,
  title={cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.},
  author={Fabrice Vandeput and Judith Krall and Ramzi A Ockaili and Fadi N. Salloum and Vincent A. Florio and Jackie D. Corbin and Sharron H. Francis and Rakesh C. Kukreja and Matthew A. Movsesian},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2009},
  volume={330 3},
  pages={884-91}
}
In mouse models of cardiac disease, the type 5 (PDE5)-selective cyclic nucleotide phosphodiesterase inhibitor sildenafil has antihypertrophic and cardioprotective effects attributable to the inhibition of cGMP hydrolysis. To investigate the relevance of these findings to humans, we quantified cGMP-hydrolytic activity and its inhibition by sildenafil in cytosolic and microsomal preparations from the left ventricular myocardium of normal and failing human hearts. The vast majority of cGMP… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Calmodulin-stimulated cyclic nucleotide phosphodiesterases, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo JA, Francis SH, and Houslay MD eds) pp 35–54

  • AT Bender
  • 2007
Highly Influential
2 Excerpts

Bench to bedside : multiple actions of the PDE 3 inhibitor cilostazol , in Cyclic Nucleotide Phosphodiesterases in Health and Disease

  • J Kambayashi, Y Shakur, Y Liu
  • J Physiol
  • 2007
1 Excerpt

Bench to bedside: multiple actions of the PDE3 inhibitor cilostazol, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo JA, Francis SH, and Houslay MD eds) pp 627–648

  • J Kambayashi, Y Shakur, Y Liu
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…